|
1
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: (Panel members). Thresholds for
therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bathe OF, Franceschi D, Livingstone AS,
Moffat FL, Tian E and Ardalan B: Increased thymidylate synthase
gene expression in liver metastases from colorectal carcinoma:
implications for chemotherapeutic options and survival. Cancer J
Sci Am. 5:34–40. 1999.PubMed/NCBI
|
|
3
|
Cascinu S, Aschele C, Barni S, Debernardis
D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P
and Catalano G: Thymidylate synthase protein expression in advanced
colon cancer: correlation with the site of metastasis and the
clinical response to leucovorin-modulated bolus 5-fluorouracil.
Clin Cancer Res. 5:1996–1999. 1999.
|
|
4
|
Leichman CG, Lenz HJ, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997.
|
|
5
|
Lenz HJ, Hayashi K, Salonga D, Danenberg
KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S,
Leichman LP and Leichman CG: p53 point mutations and thymidylate
synthase messenger RNA levels in disseminated colorectal cancer: an
analysis of response and survival. Clin Cancer Res. 4:1243–1250.
1998.PubMed/NCBI
|
|
6
|
Paradiso A, Simone G, Petroni S, Leone B,
Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ
and Johnston PG: Thymidilate synthase and p53 primary tumour
expression as predictive factors for advanced colorectal cancer
patients. Br J Cancer. 82:560–567. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Edler D, Glimelius B, Hallström M,
Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H:
Thymidylate synthase expression in colorectal cancer: a prognostic
and predictive marker of benefit from adjuvant fluorouracil-based
chemotherapy. J Clin Oncol. 20:1721–1228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnston PG, Fisher ER, Rockette HE,
Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role
of thymidylate synthase expression in prognosis and outcome of
adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol.
12:2640–2647. 1994.PubMed/NCBI
|
|
9
|
Takenoue T, Nagawa H, Matsuda K, Fujii S,
Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation
between thymidylate synthase expression and survival in colon
carcinoma, and determination of appropriate application of
5-fluorouracil by immunohistochemical method. Ann Surg Oncol.
7:193–198. 2000. View Article : Google Scholar
|
|
10
|
Yu Z, Sun J, Zhen J, Zhang Q and Yang Q:
Thymidylate synthase predicts for clinical outcome in invasive
breast cancer. Histol Histopathol. 20:871–878. 2005.PubMed/NCBI
|
|
11
|
Hakamada Y, Tsuchida A, Arima M, Kubouchi
T, Tokita H, Ota D, Kaise H and Aoki T, Kusama M and Aoki T:
Prognostic predictors in breast cancer patients with postoperative
5-fluorouracil-based chemotherapy. Int J Mol Med. 16:309–314.
2005.PubMed/NCBI
|
|
12
|
Toi M, Ikeda T, Akiyama F, Kurosumi M,
Tsuda H, Sakamoto G and Abe O: Predictive implications of
nucleoside metabolizing enzymes in premenopausal women with
node-positive primary breast cancer who were randomly assigned to
receive tamoxifen alone or tamoxifen plus tegafur-uracil as
adjuvant therapy. Int J Oncol. 31:899–906. 2007.
|
|
13
|
Etienne MC, Chéradame S, Fischel JL,
Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F
and Milano G: Response to fluorouracil therapy in cancer patients:
the role of tumoral dihydropyrimidine dehydrogenase activity. J
Clin Oncol. 13:1663–1670. 1995.PubMed/NCBI
|
|
14
|
Horiguchi J, Yoshida T, Koibuchi Y, Iijima
K, Ninomiya J, Takei H, Yokoe T, Iino Y and Morishita Y: DPD
activity and immunohistochemical DPD expression in human breast
cancer. Oncol Rep. 11:65–72. 2004.PubMed/NCBI
|
|
15
|
Metzger R, Danenberg K, Leichman CG,
Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L
and Danenberg PV: High basal level gene expression of thymidine
phosphorylase (platelet-derived endothelial cell growth factor) in
colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clin Cancer Res. 4:2371–2376. 1998.
|
|
16
|
Saito S, Tsuno N, Nagawa H, Sunami E,
Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T:
Expression of platelet-derived endothelial cell growth factor
correlates with good prognosis in patients with colorectal
carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ochiai T, Sugitani M, Nishimura K, Noguchi
H, Watanabe T, Sengoku H, Komiyama H and Okano M: Correlation
between clinical pathophysiologic factors and expression of orotate
phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and
dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (in
Japanese). Gan To Kagaku Ryoho. 29:413–420. 2002.
|
|
18
|
Ochiai T, Nishimura K, Noguchi H, Kitajima
M, Tsukada A, Watanabe E, Nagaoka I and Futagawa S: Prognostic
impact of orotate phosphoribosyl transferase among 5-fluorouracil
metabolic enzymes in resectable colorectal cancers treated by oral
5-fluorouracil-based adjuvant chemotherapy. Int J Cancer.
118:3084–3088. 2006. View Article : Google Scholar
|
|
19
|
Ichikawa W, Uetake H, Shirota Y, Yamada H,
Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama RK: Both
gene expression for orotate phosphoribosyltransferase and its ratio
to dihydropyrimidine dehydrogenase influence outcome following
fluoropyrimidine-based chemotherapy for metastatic colorectal
cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar
|
|
20
|
Kakimoto M, Uetake H, Osanai T, Shirota Y,
Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV and
Sugihara K: Thymidylate synthase and dihydropyrimidine
dehydrogenase gene expression in breast cancer predicts 5-FU
sensitivity by a histocultural drug sensitivity test. Cancer Lett.
223:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Makino H, Uetake H, Danenberg KD,
Danenberg PV and Sugihara K: Efficacy of laser capture
microdissection plus RT-PCR technique in analyzing gene expression
levels in human gastric cancer and colon cancer. BMC Cancer.
8:2102008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fukui Y, Oka T, Nagayama S, Danenberg PV,
Danenberg KD and Fukushima M: Thymidylate synthase,
dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase
mRNA and protein expression levels in solid tumors in large scale
population analysis. Int J Mol Med. 22:709–716. 2008.
|
|
23
|
Ho DH, Pazdur R, Covington W, Brown N, Huo
YY, Lassere Y and Kuritani J: Comparison of 5-fluorouracil
pharmacokinetics in patients receiving continuous 5-fluorouracil
infusion and oral uracil plus
N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res.
4:2085–2088. 1998.PubMed/NCBI
|
|
24
|
Pestalozzi BC, Peterson HF, Gelber RD, et
al: Prognostic importance of thymidylate synthase expression in
early breast cancer. J Clin Oncol. 15:1923–1931. 1997.PubMed/NCBI
|
|
25
|
Kurebayashi J, Yamamoto Y, Udagawa K,
Okubo S, Fukushima M and Sonoo H: Establishment of enzyme-linked
immunosorbent assays for thymidylate synthase and dihydropyriminide
dehydrogenase in cancer tissues. Oncol Rep. 11:973–979. 2004.
|
|
26
|
Ioachim E: Thymidine phoshorylase
expression in breast cancer: the prognostic significance and its
association with other angiogenesis related proteins and
extracellular matrix components. Histol Histopathol. 23:187–196.
2008.
|
|
27
|
Bronckaers A, Gago F, Balzarini J and
Liekens S: The dual role of thymidine phosphorylase in cancer
development and chemotherapy. Med Res Rev. 29:903–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsunoda Y, Suzuki K, Sakamoto MA, Date Y,
Sawada T, Tsunoda A and Kusano M: Evaluation of
5-fluorouracil-related genes in breast cancer to predict the effect
of adjuvant therapy with CMF (in Japanese). Gan To Kagaku Ryoho.
36:51–55. 2009.PubMed/NCBI
|
